Transient Ischemic Attack

Clinical Trial Finder

Many patients who experience transient ischemic attacks (TIAs) are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)

Condition:   Stroke
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin (Acetylsalicylic acid, BAY1019036);   Other: Rivaroxaban-Placebo;   Other: Aspirin-Placebo
Sponsors:   Bayer;   Janssen, LP;   Hamilton Health Sciences Cooperation, Population Health Research Institute
Recruiting - verified February 2015

Ischemia Care Biomarkers of Acute Stroke Etiology (BASE)

Conditions:   Ischemic Stroke;   Atrial Fibrillation;   Transient Ischemic Attacks;   Transient Cerebrovascular Events
Intervention:   Other: Biomarker blood draw
Sponsor:   Ischemia Care LLC
Recruiting - verified March 2015

Treat Stroke to Target

Conditions:   Ischemic Stroke;   Transient Ischemic Attack;   Atherosclerotic Stenosis
Interventions:   Procedure: Target : 100 mg/dL (+/-10 mg/dL);   Procedure: 70 mg/dL
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Pfizer;   AstraZeneca;   Merck Sharp & Dohme Corp.
Recruiting - verified December 2013

Reducing Risk of Recurrence

Conditions:   Stroke;   TIA;   Hypertension;   Hyperlipidemia
Interventions:   Behavioral: TI;   Behavioral: AP
Sponsor:   Department of Veterans Affairs
Active, not recruiting - verified March 2015

Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)

Conditions:   Arterial Thromboembolic Events;   Atrial Fibrillation
Interventions:   Drug: Placebo;   Drug: Dalteparin
Sponsors:   Duke University;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified February 2015

Get CardioSmart

You're Invited